The iOS version of BiospectalOptiBP is now in alpha testing, with a public beta launch expected for the second part of 2021.
FREMONT, CA: Biospectal SA, a remote patient monitoring and biosensing software startup, have raised 4.3 million dollars (€3.7 million) in seed finance headed by digital health investor SeedLink, with participation from LabCorp, Athensmed, Privilege Ventures in Switzerland, and other European and US investors.The new funds will be helpful to expand Biospectal'sOptiBPTM smartphone blood pressure monitoring app and data platform technologies globally. In January 2021, BiospectalOptiBP for Android was released in a public beta. The iOS version of BiospectalOptiBP is now in alpha testing, with a public beta launch expected for the second part of 2021.
"Biospectal's technology has the ability to transform the global network of smartphones into a connected, clinical-grade blood pressure monitoring platform that shifts clinical capabilities out of the traditional institutional settings," said Biospectal CEO and co-founder Eliott Jones. "The funding we've received will accelerate Biospectal's growth trajectory along with the appointments of Silicon Valley-based, interventional cardiologist and influential serial healthcare innovator, Dr. Fred St. Goar, MD, Tim Juergens, General Manager and co-founder of SeedLink, William Hanlon from LabCorp and KustaaPiha, successful Health Tech Entrepreneur and Investor from Athensmed to the Biospectal Board of Directors," added Reinhard Stary, Executive Chairman of the Board.
The OptiBP medical-grade software from Biospectal uses the optical lens of a smartphone camera to measure and record a user's blood pressure flow quickly. In just 20 seconds, Biospectal's patented algorithms and optical signal capture methods convert the acquired data into blood pressure results – half the time it takes a traditional blood pressure cuff.When it takes to download and install an app, anyone with a smartphone anywhere globally can convert their device into a connected, smart, clinical-grade monitor with BiospectalOptiBP.
"BiospectalOptiBP is a breakthrough technology that enables more accessible, effective, and efficient patient monitoring to empower patients to contribute to, and participate in, the clinical regimen for chronic condition monitoring and management," said Tim Juergens, General Manager, and co-founder, SeedLink. "The 'participatory patient' dynamic is accelerating and forms an integral component within the research and clinical landscape. Biospectal answers the increasing demand for telehealth solutions and will help improve the health and quality of life for millions and we are excited to support Biospectal's future success."
